Cubist Pharmaceuticals Reports Results From Phase 2 Study Hepex-B(TM), Which Was Licensed From XTLbio (Hep C Chronic Fatigue)

Cubist Pharmaceuticals Reports Results From Phase 2 Study Hepex-B(TM), Which Was Licensed From XTLbio
FinanzNachrichten - Dec 22 12:09 AM
REHOVOT, Israel, December 22 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. ( Nachrichten ) ("XTLbio") announces that Cubist Pharmaceuticals, ( Nachrichten ) Inc. today provided data from a recently concluded Phase 2 study of HepeX-B(TM) which was licensed to Cubist by XTLbio in 2004. In the Phase 2 study, HepeX-B was studied as maintenance therapy to prevent reinfection with hepatitis B Save to My Web

Human Genome Sciences Reports on Progress Toward Commercialization and Announces 2006 Goals at JPMorgan Healthcare
[Press Release] PR Newswire via Yahoo! Finance - Jan 10 4:10 AM
Human Genome Sciences, Inc. will report on its progress toward commercialization and announce 2006 goals during a presentation tomorrow by President and Chief Executive Officer H. Thomas Watkins to financial analysts and investors at the 24th Annual JPMorgan Healthcare Conference in San Francisco.Save to My Web

Human Genome Sciences Announces Decision to Spin Off CoGenesys Division as an Independent Company
[Press Release] PR Newswire via Yahoo! Finance - Dec 13 1:05 PM
Human Genome Sciences, Inc. today announced that it has decided to spin off its CoGenesys division as an independent company that will focus on the early development of selected gene-based product opportunities and the monetization of certain Human Genome Sciences intellectual property and technology assets.Save to My Web

Chronic Hepatitis C Treatment, Peg-Intron(R) And Rebetol(R) Approved In Japan
Medical News Today - Dec 27 4:15 PM
Schering-Plough Corporation (NYSE: SGP) announced that Schering-Plough K.K., the company's country operations in Japan, has received marketing approval for a new, additional indication for PEG-INTRON(R) (peginterferon alfa-2b) Powder for Injection in combination with REBETOL(R) (ribavirin) Capsules -- the treatment of chronic hepatitis C in adult patients other than those with genotype 1 virus Save to My Web

Hepatitis C Patients Taxing Medical System
HealthDay via Yahoo! News - Dec 30 11:02 AM
FRIDAY, Dec. 30 (HealthDay News) -- The use of health-care resources by hepatitis C patients in the United States has been increasing by 25 percent to 30 percent a year, says a Duke University study in the December issue of Hepatology.Save to My Web